Phase I tolerability/safety of sunitinib in combination with capecitabine in patients (pts) with advanced solid tumors

被引：0
|
作者：
Verschraegen, C. [1 ]
Sweeney, C. [2 ]
Chiorean, G. [2 ]
Lee, F. C. [1 ]
Jones, S. [3 ]
Tye, L. [4 ]
Bello, A. [5 ]
Chao, R. [4 ]
Burris, H., III
机构：
[1] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA
[2] Indiana Univ, Indiana Univ Canc Ctr, Indianapolis, IN USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Pfizer Inc, La Jolla, CA USA
[5] Pfizer Inc, New York, NY USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70513-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
714
引用
收藏
页码：111 / 111
页数：1
相关论文
共 50 条
  • [41] Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study
    Simonelli, M.
    Lorusso, D.
    Homicsko, K.
    Seguy, F.
    Kinder, M.
    Liu, Q.
    Croft, E.
    Kitano, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S495 - S495
  • [42] PHASE I SAFETY AND TOLERABILITY OF ONCE DAILY ORAL AFATINIB (A) IN COMBINATION WITH DOCETAXEL (D) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY ADVANCED SOLID TUMOURS
    Senellart, H.
    Bennouna, J.
    Isambert, N.
    De Mont-Serrat, H.
    Squiban, P.
    Tschoepe, I.
    Delord, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 169 - 169
  • [43] Safety, tolerability, and pharmacokinetics (PK) of rilotumumab in Japanese patients (pts) with advanced solid tumors.
    Doi, Toshihiko
    Tang, Rui
    Zhang, Yilong
    Loh, Elwyn
    Lizambri, Richard
    Yasui, Hirofumi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [44] Safety and tolerability of the olaparib tablet formulation in Japanese patients (pts) with advanced solid tumors (ASTs)
    Takahashi, Yasuo
    Fujikawa, Koshi
    Sagawa, Tamotsu
    Yonemori, Kan
    Tamura, Kenji
    Kodaira, Makoto
    Esaki, Taito
    Shirakawa, Tsuyoshi
    Hirai, Fumihiko
    Yokoi, Yuki
    Kawata, Toshio
    Hatano, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [46] Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
    Dean, E.
    Middleton, M. R.
    Pwint, T.
    Swaisland, H.
    Carmichael, J.
    Goodege-Kunwar, P.
    Ranson, M.
    BRITISH JOURNAL OF CANCER, 2012, 106 (03) : 468 - 474
  • [47] Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
    E Dean
    M R Middleton
    T Pwint
    H Swaisland
    J Carmichael
    P Goodege-Kunwar
    M Ranson
    British Journal of Cancer, 2012, 106 : 468 - 474
  • [48] A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors
    Lam, Elaine T.
    O'Bryant, Cindy L.
    Basche, Michele
    Gustafson, Daniel L.
    Serkova, Natalie
    Baron, Anna
    Holden, Scott N.
    Dancey, Janet
    Eckhardt, S. Gail
    Gore, Lia
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (12) : 3685 - 3694
  • [49] Inhibition of autophagy: Phase I safety, tolerability, and pharmacokinetics (PK) of hydroxychloroquine (H) in combination with vorinostat (V) in patients with advanced solid tumors
    Mahalingam, Devalingam
    Mita, Monica M.
    Sarantopoulos, John
    Wood, Leslie
    Mita, Alain C.
    Curiel, Tyler J.
    Argiris, Athanassios
    Nawrocki, Steffan T.
    Carew, Jennifer S.
    Giles, Francis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Phase I clinical, biology & pharmacokinetic study of the combination of GW 572016 and capecitabine in patients with advanced solid tumors
    Schwartz, G
    Chu, QSC
    Hammond, LA
    Mita, M
    Curtright, J
    Versola, MJ
    Koch, K
    Pandite, LN
    Ho, PTC
    Rowinsky, EK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 212S - 212S
12345